By integrating neurobiological, physiological, and translational perspectives, this review offers a novel framework for understanding vagal oxytocin receptors as therapeutic targets in disorders such as dysphagia, obesity, and functional GI syndromes. This evidence concerns the gene OXTR and obesity disorder.